FLNA
Filana Therapeutics, Inc.
NASDAQ: FLNA · HEALTHCARE · BIOTECHNOLOGY
$1.44
-7.69% today
Updated 2026-04-29
Market cap
$77.78M
P/E ratio
—
P/S ratio
2.54x
EPS (TTM)
$-1.88
Dividend yield
—
52W range
$1 – $5
Volume
0.5M
Filana Therapeutics, Inc. (FLNA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $936000.00 |
| Gross profit | — | — | — | — | $-936000.00 |
| Gross margin | — | — | — | — | — |
| R&D | $24.81M | $68.03M | $89.42M | $69.64M | $26.59M |
| SG&A | $8.05M | $11.99M | $16.53M | $71.81M | $68.80M |
| Operating income | $-32.87M | $-80.02M | $-105.96M | $-141.45M | $-95.39M |
| Operating margin | — | — | — | — | — |
| EBITDA | $-32.33M | $-80.18M | $-105.80M | $-141.15M | $-94.45M |
| EBITDA margin | — | — | — | — | — |
| EBIT | $-32.87M | $-81.48M | $-107.33M | $-142.28M | $-95.39M |
| Interest expense | — | — | — | — | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-32.38M | $-76.25M | $-97.22M | $-24.34M | $-90.97M |
| Net income growth (YoY) | — | -135.4% | -27.5% | +75.0% | -273.7% |
| Profit margin | — | — | — | — | — |